MapLight Therapeutics has made its debut on the Nasdaq, raising $251m for a lead drug that could be a rival to BMS’ new schizophrenia drug Cobenfy.
GSK strikes again, adding COPD candidate in $745m deal
In its second pipeline-expanding deal in 24 hours, GSK has licensed rights to a drug for COPD from US biotech Empirico for $85m upfront.
“We will never build a sex robot,” says Mustafa Suleyman
Mustafa Suleyman, CEO of Microsoft AI, is trying to walk a fine line. On the one hand, he thinks that the industry is taking AI in a dangerous direction by building chatbots that present as human: He worries that people will be tricked into seeing life instead of lifelike behavior. In August, he published a […]
GHO Capital gets $2.9B for fourth healthcare PE fund
European healthcare specialist GHO Capital has nabbed €2.5 billion (~$2.9 billion) for its fourth fund. The raise comes in at almost $1 billion more than GHO’s third fund …
GSK to license Empirico’s COPD candidate for $85M upfront
GSK said Tuesday it will spend $85 million upfront for an exclusive license to a Phase 1-stage small interfering RNA (siRNA) product being developed by Empirico to treat COPD. Empirico will oversee the ongoing Phase …
Startup launches with $80M and a plan to teach the immune system to make better Tregs
Can researchers train the cells inside type 1 diabetes patients to shut down the immune response that leads to their disease? A new company wants to answer that question. Zag Bio launched Tuesday with an …
Novartis could sell more drugs through direct-to-patient service
Novartis said Tuesday it is mulling making more of its medicines available through its direct-to-consumer platform in a bid to assuage President Donald Trump’s concerns about drug pricing in the US. In September, the Swiss …
Novartis’ new drugs outweigh Entresto decline in Q3
Now feeling the impact of generic competition on its top product Entresto in the US, Novartis is still looking for pipeline-building deals, says CEO.
An AI adoption riddle
A few weeks ago, I set out on what I thought would be a straightforward reporting journey. After years of momentum for AI—even if you didn’t think it would be good for the world, you probably thought it was powerful enough to take seriously—hype for the technology had been slightly punctured. First there was the […]
FAIR-RAG: Faithful Adaptive Iterative Refinement for Retrieval-Augmented Generation
arXiv:2510.22344v1 Announce Type: cross Abstract: While Retrieval-Augmented Generation (RAG) mitigates hallucination and knowledge staleness in Large Language Models (LLMs), existing frameworks often falter on complex, multi-hop queries that require synthesizing information from disparate sources. Current advanced RAG methods, employing iterative or adaptive strategies, lack a robust mechanism to systematically identify and fill evidence gaps, often […]